OTCMKTS:ARTH - Arch Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.39 -0.01 (-2.50 %)
(As of 11/16/2018 04:00 PM ET)
Previous Close$0.39
Today's Range$0.37 - $0.39
52-Week Range$0.25 - $0.80
Volume75,499 shs
Average Volume206,868 shs
Market Capitalization$57.53 million
P/E Ratio-7.80
Dividend YieldN/A
Beta0.83
Arch Therapeutics, Inc., operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.

Receive ARTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ARTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ARTH
Previous SymbolNASDAQ:ARTH
CUSIPN/A
Phone617-431-2313

Debt

Debt-to-Equity RatioN/A
Current Ratio18.77
Quick Ratio18.77

Price-To-Earnings

Trailing P/E Ratio-7.80
Forward P/E Ratio-13.00
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.01 per share
Price / Book39.00

Profitability

EPS (Most Recent Fiscal Year)($0.05)
Net Income$-7,780,000.00
Net MarginsN/A
Return on Equity-253.72%
Return on Assets-115.60%

Miscellaneous

Employees10
Outstanding Shares159,820,000
Market Cap$57.53 million
OptionableNot Optionable

Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions

What is Arch Therapeutics' stock symbol?

Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."

How were Arch Therapeutics' earnings last quarter?

Arch Therapeutics Inc (OTCMKTS:ARTH) announced its quarterly earnings results on Tuesday, May, 2nd. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.01). View Arch Therapeutics' Earnings History.

When is Arch Therapeutics' next earnings date?

Arch Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November 21st 2018. View Earnings Estimates for Arch Therapeutics.

What price target have analysts set for ARTH?

4 brokerages have issued 1-year price targets for Arch Therapeutics' stock. Their predictions range from $3.00 to $3.00. On average, they expect Arch Therapeutics' share price to reach $3.00 in the next twelve months. This suggests a possible upside of 669.2% from the stock's current price. View Analyst Price Targets for Arch Therapeutics.

What is the consensus analysts' recommendation for Arch Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arch Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arch Therapeutics.

Has Arch Therapeutics been receiving favorable news coverage?

Headlines about ARTH stock have been trending positive on Saturday, according to InfoTrie. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arch Therapeutics earned a daily sentiment score of 2.2 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days.

Who are some of Arch Therapeutics' key competitors?

Who are Arch Therapeutics' key executives?

Arch Therapeutics' management team includes the folowing people:
  • Dr. Terrence W. Norchi, Co-Founder, Pres, CEO, Sec. & Director (Age 53)
  • Mr. Richard E. Davis, Chief Financial Officer and Treasurer (Age 60)
  • Dr. Avtar S. Dhillon, Bus. Advisor (Age 57)
  • Mr. Rutledge Ellis-Behnke, Co-Founder & Scientific Advisor
  • Dr. Steven A. Kates Ph.D., VP of Technology

How do I buy shares of Arch Therapeutics?

Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Arch Therapeutics' stock price today?

One share of ARTH stock can currently be purchased for approximately $0.39.

How big of a company is Arch Therapeutics?

Arch Therapeutics has a market capitalization of $57.53 million. The biotechnology company earns $-7,780,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis. Arch Therapeutics employs 10 workers across the globe.

What is Arch Therapeutics' official website?

The official website for Arch Therapeutics is http://www.archtherapeutics.com.

How can I contact Arch Therapeutics?

Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected]


MarketBeat Community Rating for Arch Therapeutics (OTCMKTS ARTH)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  129 (Vote Underperform)
Total Votes:  263
MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote "Outperform" if you believe ARTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel